FDA Approves Use of Up To Three Tubes of Biofrontera Inc.s Ameluz Topical Gel, 10 percent In One Treatment

BFRI Stock  USD 0.87  0.11  11.22%   
Under 60% of Biofrontera's investor base is looking to short. The analysis of the overall investor sentiment regarding Biofrontera suggests that many traders are alarmed. Biofrontera's investing sentiment shows overall attitude of investors towards Biofrontera.
  
Approval allows for larger field treatment of actinic keratosis on face and scalp with Ameluz-PDT using the BF-RhodoLED or the RhodoLED XL lampSupplemental New Drug Application supported by two Phase 1 safety studiesAK is the second most common diagnosis made by dermatologists in the United States1An estimated 13 million treatments given each year for AK in the US2 WOBURN, Mass., Oct. 07, 2024 -- Biofrontera Inc. , a bi

Read at finance.yahoo.com
Yahoo News
  

Biofrontera Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Biofrontera can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Biofrontera Fundamental Analysis

We analyze Biofrontera's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biofrontera using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biofrontera based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Current Ratio

Current Ratio Comparative Analysis

Biofrontera is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Biofrontera Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biofrontera stock to make a market-neutral strategy. Peer analysis of Biofrontera could also be used in its relative valuation, which is a method of valuing Biofrontera by comparing valuation metrics with similar companies.

Peers

Biofrontera Related Equities

SBFMWSunshine Biopharma   7.75   
0%
78.0%
CPIXCumberland Pharmaceuticals   5.76   
0%
58.0%
RGCRegencell Bioscience   0.00   
0%
0%
EVOKEvoke Pharma   0.00   
0%
0%
PROCProcaps Group     
1.0%
0%
SXTCChina SXT   0.22   
2.0%
0%
PRFXPainreform   1.59   
16.0%
0%
AKANAkanda Corp   4.14   
42.0%
0%
IXHLIncannex Healthcare   4.72   
48.0%
0%
CPHIChina Pharma   7.14   
72.0%
0%
SHPHShuttle Pharmaceuticals   9.82   
100.0%
0%

Complementary Tools for Biofrontera Stock analysis

When running Biofrontera's price analysis, check to measure Biofrontera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biofrontera is operating at the current time. Most of Biofrontera's value examination focuses on studying past and present price action to predict the probability of Biofrontera's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biofrontera's price. Additionally, you may evaluate how the addition of Biofrontera to your portfolios can decrease your overall portfolio volatility.
Fundamental Analysis
View fundamental data based on most recent published financial statements
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes